<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03795558</url>
  </required_header>
  <id_info>
    <org_study_id>Etelcalcetide-T50-CKD5D</org_study_id>
    <nct_id>NCT03795558</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients</brief_title>
  <official_title>A Study to Investigate the Influence of PTH-lowering by Etelcalcetide (Parsabiv®) on the Calcification Propensity of Serum in Dialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prim. Priv. Doz. Dr. Daniel Cejka</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Elisabethinen Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-center, prospective, dose-escalation, pilot study in 15 end-stage renal&#xD;
      disease patients on chronic hemodialysis with secondary hyperparathyroidism.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fifteen prevalent and stable hemodialysis patients with secondary hyperparathyroidism&#xD;
      eligible for treatment with calcium receptor sensitizers according to current KDIGO will be&#xD;
      included.&#xD;
&#xD;
      Study phases will begin and end on the day of the first hemodialysis session of the week.&#xD;
&#xD;
      The run-in phase will last 4 weeks. No calcimimetics will be prescribed during the run-in&#xD;
      phase.&#xD;
&#xD;
      The treatment phase starts with a dose of etelcalcetide is 2.5mg thrice weekly. Etelcalcetide&#xD;
      dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose&#xD;
      of 15mg thrice weekly.&#xD;
&#xD;
      The wash-out Phase starts after completion of the 15mg thrice-weekly phase or in case a&#xD;
      pre-specified safety endpoint is reached, etelcalcetide will be discontinued and patients&#xD;
      will be followed for additional 8 weeks to study any potential reversibility of PTH lowering&#xD;
      on T50 results.&#xD;
&#xD;
      For the individual patient, the study duration will be 9 months&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a single-center, prospective, dose-escalation, pilot study. Starting dose 2.5 mg thrice weekly dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>T50-Laboratory Test for measuring calcification</measure>
    <time_frame>32 weeks</time_frame>
    <description>The changes in T50 values between the different study phases will be evaluated as the primary outcome.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>End Stage Renal Disease</condition>
  <arm_group>
    <arm_group_label>Etelcalcetide 2.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 7,5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 12,5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etelcalcetide 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etelcalcetide, starting dose of 2.5mg thrice weekly, dose will be escalated every 4 weeks in 2.5mg/dialysis session increments to a maximum dose of 15mg thrice weekly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etelcalcetide</intervention_name>
    <description>Up-Titration</description>
    <arm_group_label>Etelcalcetide 10 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 12,5 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 15 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 2.5 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 5 mg</arm_group_label>
    <arm_group_label>Etelcalcetide 7,5 mg</arm_group_label>
    <other_name>Parsabiv</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Prevalent patients (≥ 3 months on dialysis) treated with thrice weekly hemodialysis&#xD;
             (HD) or hemodiafiltration (HDF)&#xD;
&#xD;
          -  Secondary hyperparathyroidism defined as PTH levels &gt; 9x ULN according to current&#xD;
             KDIGO guidelines if therapy-naïve, or patients already treated with calcium receptor&#xD;
             sensitizers with PTH &gt; 2x ULN&#xD;
&#xD;
          -  Albumin corrected calcium ≥ 2,08 mmol/l&#xD;
&#xD;
          -  Calcium concentrations of dialysate stable for at least 2 weeks prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving treatment in another investigational device or drug study or&#xD;
             participation in non-interventional studies&#xD;
&#xD;
          -  Current treatment with etelcalcetide (Parsabiv©) or treatment with etelcalcetide&#xD;
             within 3 months prior to study inclusion&#xD;
&#xD;
          -  Patient has known sensitivity to any of the products or components of Parsabiv©&#xD;
&#xD;
          -  Patient has received a parathyroidectomy&#xD;
&#xD;
          -  Parathyroidectomy planned or expected during the study period&#xD;
&#xD;
          -  Elective kidney transplant scheduled during the study period&#xD;
&#xD;
          -  Therapy with bisphosphonates within the past 12 months&#xD;
&#xD;
          -  Therapy with denosumab within the past 6 months&#xD;
&#xD;
          -  Antacids containing aluminum, calcium, magnesium or bicarbonate&#xD;
&#xD;
          -  Patient has a history of symptomatic ventricular arrhythmias or Torsades de Pointes&#xD;
&#xD;
          -  Patient has a history of myocardial infarction, coronary angioplasty, or coronary&#xD;
             arterial bypass grafting within the past 6 months prior to screening.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Cejka, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ordensklinikum Linz GmbH Elisabethinen</name>
      <address>
        <city>Linz</city>
        <state>Upper Austria</state>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2019</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Elisabethinen Hospital</investigator_affiliation>
    <investigator_full_name>Prim. Priv. Doz. Dr. Daniel Cejka</investigator_full_name>
    <investigator_title>Head of Nephrology department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

